Short answer
Benitec Biopharma Inc. (BNTC) filed an 8-K current report with the SEC on September 14, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Fiscal-year results cover the period ended June 30, 2026.
Benitec Biopharma Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Fiscal-year results cover the period ended June 30, 2026
- Press release includes financial results and operational update
- Investor focus: Exhibit 99.1 contains detailed figures and management commentary
Item EX-99.1 · Exhibit EX-99.1
- FY2026 net loss $45.5M, or $0.98 per share, versus $37.9M and $1.05 in FY2025
- Cash $180.0M at June 30, 2026, providing funding for BB-301 development toward a planned mid-2027 pivotal trial
- All six low-dose Cohort 1 patients completed 12-month follow-up; three high-dose Cohort 2 patients safely treated
- FDA Type C meeting completed in 3Q2026 on pivotal design, with meeting minutes anticipated in October
- Interim BB-301 data presentation scheduled for October 27-30, 2026, creating a near-term clinical catalyst
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Benitec Biopharma Inc. 8-K filings
Get the next BNTC 8-K as it lands
Follow BNTC for push alerts, or ask the research agent what this filing means.